These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8237825)

  • 1. Comparative mechanisms of action of antiarrhythmic drugs.
    Nattel S
    Am J Cardiol; 1993 Nov; 72(16):13F-17F. PubMed ID: 8237825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of antiarrhythmic agents: electropharmacologic basis and clinical relevance.
    Coromilas J
    Cardiovasc Clin; 1992; 22(1):97-116. PubMed ID: 1309443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular and ionic specificity of antiarrhythmic drug actions.
    Nattel S
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute electrophysiologic effects and antiarrhythmic/antifibrillatory activity of intravenous amiodarone in a chronic feline infarction model.
    Marinchak RA; O'Connor KM; Friehling TD; Kowey PR
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):389-95. PubMed ID: 2476617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions.
    Nattel S; Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):11R-19R. PubMed ID: 10568655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity.
    Nattel S; Talajic M; Quantz M; DeRoode M
    Circulation; 1987 Aug; 76(2):442-9. PubMed ID: 3608127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maastricht antiarrhythmic drug evaluator (MANTA): A computational tool for better understanding of antiarrhythmic drugs.
    Sutanto H; Laudy L; Clerx M; Dobrev D; Crijns HJGM; Heijman J
    Pharmacol Res; 2019 Oct; 148():104444. PubMed ID: 31493513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use.
    Gonzalez ER; Kannewurf BS; Ornato JP
    Resuscitation; 1998; 39(1-2):33-42. PubMed ID: 9918445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amiodarone on Kv1.4 channel C-type inactivation: comparison of its effects with those induced by propafenone and verapamil.
    Xu L; Huang C; Chen J; Jiang X; Li X; Bett GC; Rasmusson RL; Wang S
    Pharmazie; 2008 Jun; 63(6):475-9. PubMed ID: 18604993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dronedarone: an overview.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Ann Med; 2012 Feb; 44(1):60-72. PubMed ID: 21745093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.